The Study Will Evaluate the Effect of AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

A Double-blind, Placebo-controlled, Randomised, Multi-centre, 3-way Cross-over, Single-dose Phase II Study to Investigate the Local and Systemic Effects of Inhaled AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

The purpose of this study is to investigate effects of inhaled AZD8683 compared to placebo in COPD patients.

A double-blind, placebo-controlled, randomised, multi-centre, 3-way cross-over, single-dose phase II study to investigate the local and systemic effects of inhaled AZD8683 in patients with chronic obstructive pulmonary disease (COPD)

Inclusion Criteria:

• Clinical diagnosis of COPD
• Current or ex-smokers
• FEV1 40 - 80% of the predicted normal value (post-bronchodilator) and post-bronchodilator FEV1/FVC < 70%

Exclusion Criteria:

• Any clinically significant disease or disorder
• Any clinically relevant abnormal findings at screening examinations
• Family history or presence of glaucoma
• Need of long term oxygen therapy